問卷

TPIDB > 臨床試驗主持人

臨床試驗主持人


國立台灣大學醫學院附設醫院 (在職)

心臟血管內科

內科

更新時間:2023-09-19

吳卓鍇WU, CHO-KAI
  • 計畫主持人
  • 執行臨床試驗年資 12 年 9 個月

發表文獻

23

21

Wang, T. D., Lee, Y. H., Chang, S. S., Tung, Y. C., Yeh, C. F., Lin, Y. H., Pan, C. T., Hsu, C. Y., Huang, C. Y., Wu, C. K., Sung, P. H., Chiang, L. T., Wang, Y. C., Tsai, W. C., Lin, T. T., Lin, C. P., Chen, W. J., & Hwang, J. J. (2019). 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension. Acta Cardiologica Sinica, 35(3), 199-230. https://doi.org/10.6515/acs.201905_35(3).20190415a

22

Wu, C. K., Cheng, J. F., Huang, C. Y., Chen, Z. W., Chen, S. Y., & Lin, L. Y. (2021). Iloprost and exercise haemodynamics in heart failure with preserved ejection fraction-the ILO-HOPE randomised controlled trial. British Journal of Clinical Pharmacology, 87(3), 1165-1174. https://doi.org/10.1111/bcp.14484

23

Wu, C. K., Lee, J. K., Hsu, J. C., Su, M. Y. M., Wu, Y. F., Lin, T. T., Lan, C. W., Hwang, J. J., & Lin, L. Y. (2020). Myocardial adipose deposition and the development of heart failure with preserved ejection fraction. European Journal of Heart Failure, 22(3), 445-454. https://doi.org/10.1002/ejhf.1617
1 2 3